|
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia. TELINTRA® is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
2012 Annual Report
2013 Proxy Statement
May 10, 2013
Telik Announces First Quarter 2013 Financial Results
March 15, 2013
Telik Announces Fourth Quarter and 2012 Year End Financial Results and 2013 Financial Guidance
January 22, 2013
Telik Announces Preliminary Agreement on Design of Phase 3 Registration Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome
January 11, 2013
Telik Announces Orphan Designation of Telintra® for Treatment of Myelodysplastic Syndrome
December 12, 2012
Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology
|
